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Background: Internationally there is policy support for the introduction of methadone maintenance programmes
into prison settings. Increasingly GPs are encouraged to undertake this work although concerns remain regarding
the safety of such programmes. This study sought to evaluate the impact and safety of the introduction of a
general practitioner with a special interest (GPsi) in substance misuse led methadone prescribing service into a UK
prison between 2003 and 2010.
Methods: Time series analysis of secondary prescribing data pertaining to opiate maintenance therapies, opiate
detoxification therapies and opiate related deaths for the time period 2003 to 2010.
Results: Results show that following introduction of a GPsi in substance misuse there was a statistically significant
increase in both methadone maintenance and detoxification treatments. Over time the rate of methadone
maintenance prescribing plateaued with a corresponding decrease in the rate of methadone detoxification
prescribing. There were no methadone related deaths in prison over the study period.
Conclusion: The phased introduction of opiate replacement therapies into a busy remand prison did not result in
any deaths within the prison for which opiate replacement was identified as the cause. GPsi led opiate prescribing
programmes can be introduced safely into secure environments.
Keywords: Methadone maintenance, Prison medicine, Opiates, DependenceBackground
Recently published statistics show that the prison popu-
lation for England and Wales was 84,586 at the end of
August 2010 [1]. This figure represents an increase in
the prison population of approximately 30 per cent since
1999. The increase was due to a combination of tougher
sentencing and enforcement outcomes, and a more ser-
ious mix of offence groups coming before the courts. It
equates to a prison population rate of 153/100,000 of
the national population. Internationally there are coun-
tries with a higher proportion of the population impri-
soned. For example the United States has the highest* Correspondence: natwright@nhs.net
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unless otherwise stated.prison population rate in the world with 714 per 100,000
of the national population in prison and Russia 629/
100,000 of the national population, [2].
Upon reception into prison up to 80% of offenders test
positive for either heroin or cocaine [3]. A cross-
sectional survey of a sample of the UK prison population
conducted in 1998 revealed that 38% of male remand
prisoners and 48% of sentenced prisoners admitted to
using drugs during their current period of imprison-
ment. The survey was conducted at a time when there
was very little drug treatment available in the UK prison
setting. The practice of coerced detoxification from opi-
ate maintenance was commonplace upon reception into
prison leading to a class action brought against the
Home Office for negligent drug treatment provision
whilst in prison [4]. An out of court compensationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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based drug treatment services. Compensation was pro-
vided as it was acknowledged that opiate maintenance
and detoxification therapies had significant potential to
reduce harms associated with illicit drug withdrawal.
There was an established evidence base that opiate
maintenance reduced rates of crime, illicit drug use, and
injecting practice yet prisoners were not routinely pro-
vided this treatment. Also there was an emerging UK
evidence base that rates of self-harm and suicides were
markedly increased in the week following reception into
prison and that uncontrolled symptoms of opiate with-
drawal were a contributory factor [5]. At that time the vast
majority of primary care services were provided by doctors
employed by the Home Office and not the National
Health Service (NHS). Not all practitioners offering pri-
mary care services held a certificate of accreditation in
general practice.
Nevertheless some drug users were able to become ab-
stinent whilst in prison. However in the absence of safe
prison based primary care prescribing of opiate mainten-
ance there is an increased risk of drug related death
upon release from prison. This is due to accidental over-
dose in the community if similar drug misuse practices
are re-commenced upon release following a period of
enforced abstinence in prison leading to a loss of toler-
ance to prescribed opiates. An analysis of almost 50,000
newly released prisoners in England and Wales during
the period 1998 to 2000 highlighted over 440 deaths, of
which over 250 (59%) were drug-related [6]. In the year
following release, the drug-related mortality rate was 5.2
per 1000 per annum among men and 5.9 per 1000 per
annum among women. However, all-cause mortality in
the first and second weeks following prison release for
men was 37 and 26 deaths per 1000 per annum, respect-
ively. In total, 95% of these deaths were drug-related.
All-cause mortality in the first and second weeks follow-
ing prison release for women was 47 and 38 deaths per
1000 per annum, respectively, all of which were drug-
related [6]. These data highlights the period of the first
two weeks post-release from prison as a time of high
risk for opioid-related deaths.
In June 2004, in such a context of litigation and drug
related death post prison-release, an opiate maintenance
programme was introduced into a remand prison in the
North of England with a population of approximately
1200 prisoners. The introduction was phased and pre-
ceded the widespread introduction of such programmes
across both the national and international prison estate.
Examples of the international context at that time are
that in the Australian penal system, a prison based ran-
domised controlled trial evaluating the effectiveness of
methadone maintenance had just been published [7].
Key findings were that at five-month follow-up in prison,those receiving methadone maintenance reported signifi-
cant reductions in heroin use, drug injection and syringe
sharing. Four years later, a USA randomised controlled
trial evaluating the effectiveness of prison based opiate
maintenance therapy was published. The researchers
randomly allocated two hundred and eleven users pris-
oners to either counselling in prison, with passive refer-
ral to treatment upon release; counselling and transfer
(counselling in prison with transfer to methadone main-
tenance treatment upon release); or counselling and
methadone (methadone maintenance and counselling in
prison, continued in a community-based methadone
maintenance program upon release). Key findings were
at one-month follow-up post release a higher engage-
ment in treatment and lower proportion of individuals
testing positive for illicit opiates in the group who re-
ceived prison based methadone maintenance [8]. How-
ever neither of these two trials specifically mentioned
GP involvement in the provision of opiate maintenance
to prisoner populations. We are unaware of any pub-
lished empirical research pertaining to core competen-
cies required by GPs in prescribing that has traditionally
been viewed as high risk. In response to such a gap in
the evidence base this paper reports the findings from a
time series analysis of seven years prescribing data for
opiate maintenance which took place at a time of in-
creasing international research activity evaluating the
introduction of such maintenance therapy into prison
settings.
Methods
The introduction of a methadone maintenance programme
was undertaken by a general practitioner with special inter-
est (GPsi) in substance misuse who commenced prison
based drug treatment in December 2003 in Her Majesty’s
Prison (HMP) Leeds, a remand prison with a capacity for
1283 prisoners, where the average length of stay for each
prisoner was thirteen weeks. A consensus document
between the UK Royal College of General Practitioners
(RCGP) and Royal College of Psychiatrists, supported by
the National Treatment Agency for Substance Misuse de-
fined the competencies of a GPsi as having received spe-
cific higher-level training in the management of substance
misusers in primary care, usually the Royal College of
General Practitioners’ Certificate in the management of
drug misuse in primary care, Part 2. The document recom-
mended that such practitioners can deliver a fuller range
of drug treatment services and, as a result of additional on-
going higher-level training and professional development
activity, are able to work more autonomously, accepting
referrals from generic GP colleagues, and take responsibil-
ity for more complex cases in substance misuse [9].
For the first six months from January to June 2004
methadone was not prescribed but organisational changes
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maintenance programme. Such changes included writing
a policy containing guidelines for safe prescribing, dis-
pensing and administration; and stock requisition. In June
2004 the GPsi commenced a weekly prescribing clinic for
opiate maintenance. Fifteen months later the number of
clinics was increased to five per week. All new treatment
inductions (new commencements) were seen in this clinic.
However over the following two years patients stable on
methadone maintenance treatment were followed up in
generic (ie not substance misuse specific) prison GP
clinics. Over time new inductions (commencements) onto
maintenance treatment and methadone detoxification re-
gimes were initiated in clinics run by prison GPs who had
acquired core competencies to work as a GPsi in sub-
stance misuse. “New treatment inductions” included those
who were initiated on methadone for the first time follow-
ing a clinical history consistent with opioid dependence
and a urine sample positive for either opiates, methadone
or buprenorphine. It included new treatment inductions
in either normal prison working hours or evening clinics
for patients newly received into prison. It also included
those assessed in such evening clinics where community
prescribed opiate maintenance had been disrupted due to
an absence of methadone prescribing in police custody at
the time the study was taking place. Repeat treatment in-
ductions were excluded from analysis. Such patients in-
cluded those who were re-imprisoned during the study
period who had previously been included as a “new treat-
ment induction”. Methadone prescribing for both main-
tenance and detoxification was initiated at a dose of
30 mg daily if the patient was assessed on first night re-
ception, and at a dose of 20 mg daily if the patient was
assessed in the routine prison clinic. The rationale for
such prescribing regimes was that compared to patients
presenting in routine clinics, patients presenting at first
night prison reception typically both reported and exhib-
ited more severe symptoms and signs of withdrawal. Sub-
sequently for those receiving a detoxification regime at an
initial dose of 20 mg od (once daily), the dose would be in-
creased the following day to 30 mg od for a period of six
days prior to a reducing regime from 30 mg od to zero
over a two week period. In total such a prescribing regime
would be of three weeks duration. For those receiving a
maintenance prescribing regime at an initial dose of
20 mg od, the dose would be increased the following day
to 30 mg od. Any subsequent increases would only take
place following review by a GP. Subsequently published
national guidelines for prison recommend that “to ensure
patient safety within this context, methadone treatment
programmes should be established through a process of
dose induction. Initial doses of five to ten milligrams of
methadone (1 mg in 1 ml mixture) are to be given, at least
six hours apart” [10]. National guidelines published in2007 pertaining to drug treatment recommended “in
general, the initial daily dose will be in the range of
10–30 mg. If tolerance is low or uncertain then 10–
20 mg is more appropriate. With heavily dependent
misusers who are tolerant, and where the clinician is
experienced or competent, a first dose can be up to
40 mg but it is unwise to exceed this dose” [11].
Anonymised secondary data for both maintenance and
detoxification treatments was retrieved from the Phar-
macy Manager prison pharmacy dispensing databases
for the period covering the start of January 2003 to end
March 2010. Once retrieved, the data was aggregated
into discrete three month time periods according to the
date of first receipt of a methadone prescription. Metha-
done prescribing was introduced into the prison in May
2004. Therefore by obtaining data at equally- spaced
time intervals (ie. three month time periods) both pre
and post-intervention, it was possible to analyse by an
interrupted time-series methodology. Durbin-Watson
statistics were used to test for serial correlation (a rela-
tionship between values separated from each other by a
given time lag). The trend component of this time-series
is examined to determine the long-term variation of the
trends in prescribing methadone maintenance and de-
toxification therapies in the prison and community. The
basic model: Yt = bo + b1T + b2D + b3P + et, where T is
time from the start of the observational period, D is a
dummy variable for pre or post intervention and P is
time since the intervention; et is the random variation at
time t not explained by the model. Ordinary Least
Squares regression was undertaken to analyse prescribing
trends over time, with 3 independent variables: T – time,
D – dummy for pre-post intervention and P – time since
the intervention. The model can determine the change
over time before the intervention was implemented,
change in the outcome measure from the last time point
before the intervention to the first time point after the
intervention, and the difference in the slope of the time
period before the intervention and the slope of the time
period after the intervention. Ordinary least squares re-
gression assumes that the error terms associated with
each observation (time point) are uncorrelated. Prior to
data extraction we discussed the proposed research with
Wales Medical Research Ethics Committee who advised
that formal ethical approval was not required as the study
was a service evaluation using anonymised aggregated
secondary data from a service in which the principal in-
vestigator conducted routine clinical work.Results
Over the study period a total of 4551 patients were
inducted onto methadone maintenance and 3181 pa-
tients received a detoxification treatment.
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uals receiving maintenance prescriptions rise steadily
from its introduction in 2004, to 282 in April - June
2007. Subsequently, prescriptions remain within the
range of 245-311 until October - December 2009, where
they fall to 216 before rising slightly at the beginning of
2010 to 232.
Figure 1 shows the number of inductions “new com-
mencements” maintenance and detoxification episodes
between the time period start of January 2003 to end of
March 2010 and this is displayed in table format in
Table 1.
Ordinary least squares regression was undertaken to
analyse prescribing trends over time. Durbin-Watson
statistics to test for serial correlation of the error terms
was not significant (p = 0.556), meaning that there was
no autocorrelation. The trend prior to intervention was
flat (p = .978), as would be expected. Following the inter-
vention of GPsi prescribing there was an increase in pa-
tients receiving maintenance (Graph 1), but this was not
significant (p = 0.085). Also there was no significant
change in trend immediately after the intervention
(0.494). However over time post the intervention of a
GPsi there is a statistically significant increase for
methadone maintenance treatment episodes (p = 0.002).
As regards the results for detoxification treatments, prior
to the time-point April - July 2006, detoxification treat-
ments appear to have been preferred to maintenance. The
number of detoxification prescriptions rose dramatically
from 18 (April-June 2005) to 255 (October – December
2005), staying higher than those for methadone until the
end of 2006, when they fell to 161. There then appears toFigure 1 Number of individuals commenced on Methadone for eitherbe a rapid increase in detoxification therapies pre-
scribed in January-March 2007, reaching 277. However
after this increase, methadone detoxification prescrip-
tions have remained lower than those for methadone
maintenance and have decreased steadily from 277 at
the beginning of 2007 to 67 in January – March 2010.
Ordinary least squares regression was undertaken to
analyse prescribing trends over time. Durbin-Watson
statistics to test for serial correlation of the error terms
was not significant (p = 0.597), meaning that there was
no autocorrelation. The trend prior to intervention was
flat (p = 0.935), as would be expected. Following the
intervention of GPsi prescribing there was an increase
in patients receiving detoxification (Graph 1), which
was significant (p = 0.016). There was no significant
change in trend after the intervention (p = 0.864). How-
ever over time post the intervention of a GPsi there
was no statistically significant increase in detoxification
treatment episodes (p = 0.619).
Drug-related deaths
There were no opioid related deaths in the prison over
the study period prior to the introduction of methadone
maintenance treatment. During the time period of 2003-
2010 there was one death of a patient receiving metha-
done treatment at the time of death. His death occurred
in 2006 one week after initiation of methadone at a daily
dose of 30 mg. However toxicology investigations
highlighted the illicit use of mirtazapine, a sedative anti-
depressant [12]. At inquest the coroner reported that
the prescribing of methadone maintenance was appro-
priate in this case and therefore, this patient’s death wasMaintenance or Detoxification at HMP Leeds from 2003-2010.
Table 1 Numbers of methadone maintenance and
detoxification new treatments issued from 2003-2010






Jan-Mar 2003 4 0
Apr-Jun 2003 0 0
Jul-Sep 2003 0 0
Oct-Dec 2003 0 0
Jan-Mar 2004 0 1
Apr-Jun 2004 1 0
Jul-Sep 2004 0 10
Oct-Dec 2004 9 8
Jan-Mar 2005 37 12
Apr-Jun 2005 76 18
Jul-Sep 2005 121 138
Oct-Dec 2005 124 255
Jan-Mar 2006 136 202
Apr-Jun 2006 140 193
Jul-Sep 2006 171 188
Oct-Dec 2006 220 161
Jan-Mar 2007 254 277
Apr-Jun 2007 282 226
Jul-Sep 2007 264 208
Oct-Dec 2007 250 207
Jan-Mar 2008 245 147
Apr-Jun 2008 307 143
Jul-Sep 2008 311 150
Oct-Dec 2008 306 154
Jan-Mar 2009 309 144
Apr-Jun 2009 239 100
Jul-Sep 2009 297 100
Oct-Dec 2009 216 72
Jan-Mar 2010 232 67
TOTAL 4551 3181
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are no methadone related deaths recorded at HMP
Leeds since its introduction in 2004.
Discussion
Following the intervention of a GPsi led prescribing ser-
vice for substance misuse there was a steady increase
over the following four and half years in patients being
initiated onto methadone maintenance. The fact that the
increase only became statistically significant over time is
evidence that the implementation was phased to ensure
that the system was safe. From the time-point April-
June 2008 a further increase in the number of patientsbeing initiated onto methadone maintenance is evidence
of a second prison based GPsi receiving the core compe-
tencies to work with substance misuse and the practice
of methadone induction therefore becoming normalised
in the prison healthcare department.
Following the introduction of a GPsi led prescribing
service there was an immediate statistically significant
increase in patients receiving detoxification regimes.
However two years after the introduction there was a
decline in detoxification prescribing, the decline starting
in the time-point April-June 2006. This can be explained
by the fact that the local prescribing protocol changed.
Initially due to pressure on the service a patient could
only be initiated onto opiate maintenance if they had
failed to become abstinent upon completion of a detoxi-
fication regime. However as over 80% of drug users in
the prison failed to achieve abstinence [13], the protocol
was changed to permit patients to be inducted onto
methadone maintenance where appropriate. In the time-
point January -March 2007 there was a further increase
in methadone detoxification treatments. This can be ex-
plained by the recruitment of a new GP who at the time
of recruitment did not possess the core competencies of a
GPsi. Therefore the prescribing interventions of the GP
were limited to offering detoxification (and not mainten-
ance) regimes. As the GP acquired the core competencies
to practice as a GPsi, the number of maintenance treat-
ments continued to rise and over time a corresponding
fall in detoxification treatments.
In 2001, a UK based taskforce highlighted that the
prison environment can be a difficult and complex one
in which to work as a doctor. It highlighted that the na-
ture of the prisoner population meant that prison based
doctors would require particular skills in dealing with al-
cohol and substance misuse. It also highlighted the in-
herent risks of professional isolation working in prison
settings and recommended that the priority should be in
developing a robust structure of primary care provision
in prison settings [14]. A key clinical governance con-
cern was that not all doctors providing primary care ser-
vices in the UK prison estate at that time were trained in
the skills of general practice. In 2001 the UK Royal Col-
lege of General Practitioners commenced a training unit
dedicated to training general practitioners in the know-
ledge and skills required to competently offer treatment
to drug users. At the time of writing, since the inception
of this course 14,137 individuals have been trained in
the basics of drug treatment and 2016 have received
training to confer the competencies required to practice
as a GPsi in substance misuse [15]. We would suggest
that the RCGP has learned lessons that can be dissemi-
nated internationally. The RCGP through the Membership
of Royal College of General Practitioners International
academic examination currently has a successful formula
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competencies. The challenge for the RCGP will be how it
can replicate this successful generic international primary
care model in the field of primary care drug treatment.
We would suggest that networking with international pol-
icy leads, and international marketing of training pro-
grammes are key to disseminating best training practice.
International data pertaining to the background of doctors
providing primary care based drug treatment in prison
settings is lacking. It is possible that other countries are fa-
cing similar clinical governance concerns regarding the
safety of prison primary care based drug treatment. There
is evidence from research conducted in the Belgian prison
healthcare service of prisoners consulting the GP 3.8 times
more than a demographically equivalent population in the
community [16]. The high consultation rate was explained
in part by health concerns relating to drug misuse. How-
ever there is a paucity of research evaluating primary care
based drug treatment provision. Clearly if internationally
prisoners are high users of primary care services then gen-
eral practitioners who have received training in the
provision of safe drug treatment will be key to increasing
the international provision of prison based drug treat-
ment. It would not be our aspiration that such general
practitioners would necessarily adopt the UK title of
“general practitioner with a special interest”. Rather the
purpose of this paper has been in describing the core
competencies to ensure safe primary care provision. It is
the competencies rather than the terminology that we
would wish to share with the international readership.
The main strength of this research is in highlighting
that such primary care development is possible and that
methadone replacement therapies can safely be intro-
duced into prison settings providing such a practice is
by GPs possessing a GPsi level of core competency.
Additionally generic GPs are able to safely offer detoxifi-
cation regimes within clear prescribing protocols. This is
an important message to the GP field. The burden of in-
vestigation upon GPs practicing in secure environments
is intense. In the UK, every death in custody is by statute
subject to scrutiny by Coroner’s Inquiry [17] and investi-
gation by the Prisons and Probation Ombudsman [18].
Therefore GPs seeking to provide opiate maintenance
therapies in the prison setting should only do so having
undertaken either further training or supervision in the
management of substance misuse. In 2007, the World
Health Organisation through its Health in Prisons Pro-
ject recommended opiate maintenance therapies are
made more widely available across the international
prison estate [19]. Our research has provided a primary
care workforce model which will be able to facilitate the
safe and effective implementation of this key international
policy recommendation. A primary care workforce is crit-
ical to increasing availability of drug treatment. Indeed in1978 the WHO endorsed the critical importance of pri-
mary care organisations as the central focus for promoting
improvements in population health [20].
The main limitation of this research is that it is limited
to prescribing data collated at one remand prison and
therefore we would be confident that our findings could
be generalised with confidence only to remand prisons
with similar health needs relating to substance misuse.
Also it was not possible to cross-check our data against
coronial records to evaluate the impact of the programme
upon opioid related deaths post release from prison. We
suggest this is an area for future research activity. Also our
research did not collect data pertaining to buprenorphine
medication as this was not routinely prescribed in the
prison at the time of initiating data collection. The reason
for this was that the UK prisons at that time had wide-
spread problems regarding buprenorphine abuse and
therefore prescribing of such medication was not encour-
aged [21].
Our research has shown that a GPsi led prison drug
treatment service is safe if on first night reception the
first induction dose of methadone does not exceed
30 mg and if in routine “outpatient” prison clinics the
first induction dose of methadone does not exceed
20 mg. This provides evidence for future reviews of
current UK national prison clinical guidelines which cur-
rently recommend a more cautious approach of initial
induction at doses of methadone 5-10 mg given at least
six hours apart” [10]. Not every prison will have access
to a GPsi. However increasingly clinical leads in prisons
are practicing at a GPsi level of competency and our
findings would support higher initial induction doses be-
ing prescribed in prison first night reception centres.
In demonstrating that methadone maintenance pre-
scribing can be safely introduced into prison settings,
our findings raise questions regarding long-term out-
comes of patients receiving such maintenance treatment.
The outcomes of survival, re-offending, abstinence and
retention in treatment post-release are all areas that
merit future research activity. Also comparing prescrib-
ing data between prisons internationally would facilitate
the comparing of clinical standards and frameworks and
lead to enhanced sharing of international best practice.
Future research activity should also analyse prescribing
data for buprenorphine as this is increasingly being used
for both maintenance and detoxification in prison settings.
Conclusion
In summary our research has highlighted that a GPsi led
phased implementation of methadone maintenance into
prisons does not compromise patient safety.
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